Compare Lamb Weston Holdings Inc (LW) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lamb Weston Holdings Inc vs Novo Nordisk A/S — how do they compare? Lamb Weston Holdings Inc trades at $48.42 (market cap $6.81B), while Novo Nordisk A/S trades at $38.47 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 24.3× Lamb Weston Holdings Inc's market cap, and Novo Nordisk A/S pays the higher dividend (4.71%). Which is the better fit depends on your goals — on Pluang, investors hold Lamb Weston Holdings Inc for 66 Days and Novo Nordisk A/S for 116 Days on average.
| LW | NVO | |
|---|---|---|
Market Cap | $6.81B | $165.31B |
Volume | 4,638,686 | 11,432,838 |
Sector | Consumer Staples | Health |
52-Week High | $66.57 | $63.98 |
52-Week Low | $38.48 | $35.29 |
Typical Hold Time | 66 Days | 116 Days |
Enterprise Value | $10.61B | $179.56B |
Dividend Yield | 3.07% | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lamb Weston (LW) trades at $48.36, up 0.56% on the day, with a bullish technical signal and consistent earnings beats in recent quarters. The stock shows strong profitability with a 14.17% ROE and trades at a P/E of 27.03. Recent news highlights cost savings exceeding $100 million and anticipation for Q1 2026 earnings. The consensus price target is $53.71, suggesting potential upside from current levels.
The outlook is cautiously optimistic given earnings momentum and analyst support, but risks include margin pressure from rising costs and ongoing legal scrutiny. Net income margin declined to 3.85% in 2025 from 11.21% in 2024, reflecting operational challenges. Investor sentiment is mixed amid institutional positioning shifts and pending earnings results.
Novo Nordisk (NVO) trades at $38.41, up 0.38% with strong fundamentals including 35.35% net margin and consistent earnings beats. The stock shows bearish technical signals but maintains robust profitability with $102.43B net income. Recent news highlights pipeline developments including Wegovy pill data and FDA reviews, while competition with Eli Lilly intensifies in the obesity drug market.
NVO presents a compelling value opportunity with a 9.66 P/E ratio and 59% upside to the $44.67 consensus target. However, technical weakness and competitive pressures from Lilly's new drug candidates pose near-term risks. The company's strong cash flow generation and 59.82% ROE support long-term growth prospects despite regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lamb Weston Holdings Inc
Lamb Weston is the world's second-largest producer of branded and private-label frozen potato products, such as French fries, sweet potato fries, tater tots, diced potatoes, mashed potatoes, hash browns, and chips. The company also has a small appetizer business that produces onion rings, mozzarella sticks, and cheese curds. Including joint ventures, 63% of fiscal 2022 revenue was U.S.-based, with the remainder stemming from Europe, Canada, Japan, China, Korea, Mexico, and several other countries. Lamb Weston's customer mix is estimated 58% quick-serve restaurants, 19% full-service restaurants, 8% other food services (hotels, commercial cafeterias, arenas, schools), and 16% retail. Lamb Weston became an independent company in 2016 when it was spun off from Conagra.
Read more on LW →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
